Suvretta Capital Management, LLC Aeglea Bio Therapeutics, Inc. Transaction History

Suvretta Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	BUY	$1.87 - $4.77 $2.78 Million - $7.1 Million	1,488,894 Added 57.91%	4,059,894 $9.34 Million
Q4 2021 Feb 14, 2022	BUY	$3.5 - $8.42 $1.45 Million - $3.48 Million	413,273 Added 19.15%	2,571,000 $12.2 Million
Q3 2021 Nov 15, 2021	BUY	$6.03 - $7.95 $383,670 - $505,834	63,627 Added 3.04%	2,157,727 $17.2 Million
Q2 2021 Aug 16, 2021	BUY	$6.32 - $8.38 $4.59 Million - $6.09 Million	727,027 Added 53.18%	2,094,100 $14.6 Million
Q1 2021 May 17, 2021	BUY	$6.76 - $8.57 $4.11 Million - $5.21 Million	608,334 Added 80.18%	1,367,073 $10.8 Million
Q4 2020 Feb 16, 2021	BUY	$7.02 - $9.83 $1.61 Million - $2.26 Million	229,639 Added 43.4%	758,739 $5.97 Million
Q3 2020 Nov 16, 2020	BUY	$6.51 - $9.33 $2.68 Million - $3.84 Million	411,171 Added 348.66%	529,100 $3.75 Million
Q2 2020 Aug 14, 2020	BUY	$4.01 - $11.04 $472,895 - $1.3 Million	117,929 New	117,929 $1.09 Million

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Suvretta Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Suvretta Capital Management, LLC with notifications on news.